Jianhua Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jianhua Li has a total of 99 co-authors. Here are the top co-authors by number of shared publications:
Jiaxuan Li
Zhejiang Key Laboratory of Public Health Detection and Pathogenesis Research, Department of Microbiology, Zhejiang Provincial Center for Disease Control Prevention
17 shared publications- Yanjun Zhang
Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China
15 shared publications - Keda Chen
Key Laboratory of Artificial Organs and Computational Medicine in Zhejiang Province, Shulan International Medical College, Zhejiang Shuren University
13 shared publications Keda Chen
5 shared publicationsXiaotian Tie
Key Laboratory of Artificial Organs and Computational Medicine of Zhejiang Province, Shulan International Medical College, Zhejiang Shuren University, Hangzhou, PR China
5 shared publicationsHao Wu
Key Laboratory of Artificial Organs and Computational Medicine of Zhejiang Province, Shulan International Medical College, Zhejiang Shuren University, Hangzhou, PR China
4 shared publications
Latest Publications
- Open Access
- 6 October 2026
- Published by Frontiers Media SA in Frontiers in Microbiology
- Vol. 17, 1960039
Arbovirus diagnostics: from conventional methods to emerging technologies—a chikungunya virus-centric review
Arboviruses remain an important global health concern because of their expanding distribution, diverse transmission patterns, and the challenges associated with accurate and timely diagnosis. This review is centered on Chikungunya virus (CHIKV) as a representative model, focusing on diagnostic strategies across different stages of infection and the key diagnostic pitfalls that affect CHIKV detection in co-circulation settings. In this review, we summarize current laboratory-based approaches for CHIKV detection and differential diagnosis, including virus isolation, antigen detection, nucleic acid amplification and serological assays, with discussion of their applications, strengths and limitations. We further review recent developments in emerging diagnostic technologies, including next-generation sequencing, CRISPR-based detection methods, aptamer-based recognition systems, biosensors, and point-of-care testing platforms, highlighting their potential advantages and current limitations. Comparative examples involving dengue virus (DENV) and Zika virus (ZIKV) are discussed specifically to illustrate cross-reactivity and misclassification risks relevant to CHIKV diagnosis. Particular attention is given to persistent issues affecting diagnostic accuracy and practical implementation, including serological cross-reactivity among co-circulating arboviruses and the challenges of translating advanced technologies into accessible tools for field and resource-limited settings. Overall, this review summarizes progress in CHIKV-relevant diagnostics and outlines future opportunities for developing more reliable, rapid, and widely applicable detection strategies.
- 6 October 2026
- Published by Frontiers Media SA in Frontiers in Microbiology
- Vol. 17, 1960039
Open AccessArbovirus diagnostics: from conventional methods to emerging technologies—a chikungunya virus-centric review
Arboviruses remain an important global health concern because of their expanding distribution, diverse transmission patterns, and the challenges associated with accurate and timely diagnosis. This review is centered on Chikungunya virus (CHIKV) as a representative model, focusing on diagnostic strategies across different stages of infection and the key diagnostic pitfalls that affect CHIKV detection in co-circulation settings. In this review, we summarize current laboratory-based approaches for CHIKV detection and differential diagnosis, including virus isolation, antigen detection, nucleic acid amplification and serological assays, with discussion of their applications, strengths and limitations. We further review recent developments in emerging diagnostic technologies, including next-generation sequencing, CRISPR-based detection methods, aptamer-based recognition systems, biosensors, and point-of-care testing platforms, highlighting their potential advantages and current limitations. Comparative examples involving dengue virus (DENV) and Zika virus (ZIKV) are discussed specifically to illustrate cross-reactivity and misclassification risks relevant to CHIKV diagnosis. Particular attention is given to persistent issues affecting diagnostic accuracy and practical implementation, including serological cross-reactivity among co-circulating arboviruses and the challenges of translating advanced technologies into accessible tools for field and resource-limited settings. Overall, this review summarizes progress in CHIKV-relevant diagnostics and outlines future opportunities for developing more reliable, rapid, and widely applicable detection strategies.
- Open Access
- 25 August 2026
- Published by Wiley in Journal of Medical Virology
- Vol. 98 (8) , e71119
Enhanced Immunogenicity and Cross‐Neutralizing Activity of a Trivalent Adenoviral Vector‐Based SARS‐CoV‐2 Vaccine in Mice
The emergence of diverse SARS‐CoV‐2 Omicron subvariants has reduced the efficacy of existing vaccines, highlighting the need for multivalent vaccines with broader neutralizing capacity. We developed a trivalent adenoviral vector‐based vaccine (Ad5‐CoV19‐prototype/Delta/BF.7) encoding the spike proteins of the ancestral strain, Delta variant, and Omicron BF.7 strain, and evaluated its immunogenicity in BALB/c mice. Four‐ to 6‐week‐old female BALB/c mice were intramuscularly immunized with 10 µg of monovalent or trivalent vaccines using single‐dose or two‐dose (2‐week interval) regimens. Neutralizing antibody (nAb) titers against the ancestral strain, Omicron BA.5, and XBB.1.5, as well as IFN‐γ + T‐cell responses, were measured. The trivalent vaccine elicited significantly higher nAb titers against the ancestral strain (GMT 2183.6 at week 8) and Omicron subvariants (BA.5: GMT 680.0; XBB.1.5: GMT 161.3) after two doses compared to monovalent vaccines. Two doses also enhanced IFN‐γ + CD8 + T‐cell responses ( p < 0.0001). These results demonstrate that the trivalent vaccine induces enhanced immunogenicity and cross‐neutralizing activity, including improved cross‐neutralizing antibody titers and IFN‐γ + T‐cell responses against multiple SARS‐CoV‐2 variants compared to monovalent formulations. These findings suggest potential for broader immune coverage against antigenically drifted variants, although protective efficacy remains to be confirmed in viral challenge models and further clinical evaluation.
- 25 August 2026
- Published by Wiley in Journal of Medical Virology
- Vol. 98 (8) , e71119
Open AccessEnhanced Immunogenicity and Cross‐Neutralizing Activity of a Trivalent Adenoviral Vector‐Based SARS‐CoV‐2 Vaccine in Mice
The emergence of diverse SARS‐CoV‐2 Omicron subvariants has reduced the efficacy of existing vaccines, highlighting the need for multivalent vaccines with broader neutralizing capacity. We developed a trivalent adenoviral vector‐based vaccine (Ad5‐CoV19‐prototype/Delta/BF.7) encoding the spike proteins of the ancestral strain, Delta variant, and Omicron BF.7 strain, and evaluated its immunogenicity in BALB/c mice. Four‐ to 6‐week‐old female BALB/c mice were intramuscularly immunized with 10 µg of monovalent or trivalent vaccines using single‐dose or two‐dose (2‐week interval) regimens. Neutralizing antibody (nAb) titers against the ancestral strain, Omicron BA.5, and XBB.1.5, as well as IFN‐γ + T‐cell responses, were measured. The trivalent vaccine elicited significantly higher nAb titers against the ancestral strain (GMT 2183.6 at week 8) and Omicron subvariants (BA.5: GMT 680.0; XBB.1.5: GMT 161.3) after two doses compared to monovalent vaccines. Two doses also enhanced IFN‐γ + CD8 + T‐cell responses ( p < 0.0001). These results demonstrate that the trivalent vaccine induces enhanced immunogenicity and cross‐neutralizing activity, including improved cross‐neutralizing antibody titers and IFN‐γ + T‐cell responses against multiple SARS‐CoV‐2 variants compared to monovalent formulations. These findings suggest potential for broader immune coverage against antigenically drifted variants, although protective efficacy remains to be confirmed in viral challenge models and further clinical evaluation.
- Open Access
- 3 August 2026
- Published by Springer Nature in Molecular Biomedicine
- Vol. 7 (1) , 122
ACE2-PNA conjugates exploit viral endocytosis for targeted intracellular delivery and exhibit dual antiviral efficacy against SARS-CoV-2
The COVID-19 pandemic and its protracted consequences underscore the urgent need for more effective antiviral strategies. Current antiviral strategies face a persistent challenge achieving sufficient viral suppression while minimizing off-target toxicity, particularly against such highly mutable viruses. Here, we describe a Receptor-Drug Conjugate (RDC) strategy, in which a therapeutic payload is covalently linked to a decoy receptor, enabling virus-triggered targeted intracellular delivery. Angiotensin-converting enzyme 2 (ACE2), as the essential receptor for SARS-CoV-2 entry, has been widely exploited for virus-neutralizing strategies. Targeting SARS-CoV-2 as a proof-of-concept, we conjugated peptide nucleic acids (PNAs) designed to target the viral ORF1ab region (±30 bp) to ACE2-Fc. The ACE2-PNA conjugate demonstrated superior inhibitory efficacy against multiple SARS-CoV-2 variants relative to ACE2-Fc alone. We confirmed that ACE2-PNA retains the extracellular neutralization activity of soluble ACE2, while being selectively internalized into virus-infected cells via virus-mediated endocytosis. Owing to its inherent protease resistance, the PNA component remains intact upon cytoplasmic entry and subsequently exerts antisense inhibitory activity against viral RNA. The mechanistic feasibility of ACE2-PNA was further validated in a mouse model. Collectively, RDC represents a novel virus-triggered targeted delivery platform that confers dual antiviral efficacy through extracellular virion neutralization and intracellular inhibition of viral replication. It has significant implications for reducing off-target toxicity and enhancing antiviral potency, and is furthermore readily adaptable to diverse viral pathogens and therapeutic payloads.
- 3 August 2026
- Published by Springer Nature in Molecular Biomedicine
- Vol. 7 (1) , 122
Open AccessACE2-PNA conjugates exploit viral endocytosis for targeted intracellular delivery and exhibit dual antiviral efficacy against SARS-CoV-2
The COVID-19 pandemic and its protracted consequences underscore the urgent need for more effective antiviral strategies. Current antiviral strategies face a persistent challenge achieving sufficient viral suppression while minimizing off-target toxicity, particularly against such highly mutable viruses. Here, we describe a Receptor-Drug Conjugate (RDC) strategy, in which a therapeutic payload is covalently linked to a decoy receptor, enabling virus-triggered targeted intracellular delivery. Angiotensin-converting enzyme 2 (ACE2), as the essential receptor for SARS-CoV-2 entry, has been widely exploited for virus-neutralizing strategies. Targeting SARS-CoV-2 as a proof-of-concept, we conjugated peptide nucleic acids (PNAs) designed to target the viral ORF1ab region (±30 bp) to ACE2-Fc. The ACE2-PNA conjugate demonstrated superior inhibitory efficacy against multiple SARS-CoV-2 variants relative to ACE2-Fc alone. We confirmed that ACE2-PNA retains the extracellular neutralization activity of soluble ACE2, while being selectively internalized into virus-infected cells via virus-mediated endocytosis. Owing to its inherent protease resistance, the PNA component remains intact upon cytoplasmic entry and subsequently exerts antisense inhibitory activity against viral RNA. The mechanistic feasibility of ACE2-PNA was further validated in a mouse model. Collectively, RDC represents a novel virus-triggered targeted delivery platform that confers dual antiviral efficacy through extracellular virion neutralization and intracellular inhibition of viral replication. It has significant implications for reducing off-target toxicity and enhancing antiviral potency, and is furthermore readily adaptable to diverse viral pathogens and therapeutic payloads.
- Open Access
- 22 May 2026
- Published by Wiley in Aging Cell
- Vol. 25 (6) , e70548
Immunosenescence and Vaccine Efficacy in Aging: Dynamic Interplay of Gut Microbiota and mTOR Signaling Pathways
Aging significantly impairs vaccine efficacy in older adults, driven by immunosenescence, inflammaging, and disruptions in the gut microbiota‐mTOR‐immune axis. This review synthesizes current evidence on how aging alters vaccine‐induced immune responses through the interplay of gut microbiota dysbiosis and dysregulated mTOR signaling. Age‐related microbial diversity declines and reduced short‐chain fatty acid (SCFA) production exacerbate inflammation, while heightened mTOR activity suppresses autophagy, promotes pro‐inflammatory states, and impairs T/B cell function, collectively diminishing antibody production and immune memory formation. We highlight the bidirectional interaction between SCFAs and mTOR, where SCFAs mitigate mTOR overactivation to enhance immune regulation, and mTOR dysregulation further aggravates microbial dysbiosis, forming a vicious cycle. Critically, this review systematically stratifies the evidence, distinguishing preclinical mechanistic insights from correlative human data. Animal and human studies suggest that targeting this axis—via mTOR inhibitors, probiotics, or dietary interventions—holds promise for improving vaccine responses in the elderly. We propose future research directions, including personalized vaccine strategies leveraging microbiota profiling and mTOR modulation, to address the challenges of infection in aging populations and advance precision medicine for healthy aging.
- 22 May 2026
- Published by Wiley in Aging Cell
- Vol. 25 (6) , e70548
Open AccessImmunosenescence and Vaccine Efficacy in Aging: Dynamic Interplay of Gut Microbiota and mTOR Signaling Pathways
Aging significantly impairs vaccine efficacy in older adults, driven by immunosenescence, inflammaging, and disruptions in the gut microbiota‐mTOR‐immune axis. This review synthesizes current evidence on how aging alters vaccine‐induced immune responses through the interplay of gut microbiota dysbiosis and dysregulated mTOR signaling. Age‐related microbial diversity declines and reduced short‐chain fatty acid (SCFA) production exacerbate inflammation, while heightened mTOR activity suppresses autophagy, promotes pro‐inflammatory states, and impairs T/B cell function, collectively diminishing antibody production and immune memory formation. We highlight the bidirectional interaction between SCFAs and mTOR, where SCFAs mitigate mTOR overactivation to enhance immune regulation, and mTOR dysregulation further aggravates microbial dysbiosis, forming a vicious cycle. Critically, this review systematically stratifies the evidence, distinguishing preclinical mechanistic insights from correlative human data. Animal and human studies suggest that targeting this axis—via mTOR inhibitors, probiotics, or dietary interventions—holds promise for improving vaccine responses in the elderly. We propose future research directions, including personalized vaccine strategies leveraging microbiota profiling and mTOR modulation, to address the challenges of infection in aging populations and advance precision medicine for healthy aging.
- Open Access
- 17 April 2026
- Published by Elsevier in Molecular Therapy Nucleic Acids
- Vol. 37 (2) , 102935
The potential and challenges of circular RNA in the development of vaccines and drugs for emerging infectious diseases
- 17 April 2026
- Published by Elsevier in Molecular Therapy Nucleic Acids
- Vol. 37 (2) , 102935
Open AccessThe potential and challenges of circular RNA in the development of vaccines and drugs for emerging infectious diseases
- 5 February 2026
- Published by Elsevier in Cytokine & Growth Factor Reviews
- Vol. 88, 108-123
Cytokine storm divergence in viral infections of the upper respiratory tract
- 5 February 2026
- Published by Elsevier in Cytokine & Growth Factor Reviews
- Vol. 88, 108-123
Cytokine storm divergence in viral infections of the upper respiratory tract
- Open Access
- 24 December 2025
- Published by Elsevier in Molecular Therapy
- Vol. 34 (4) , 1921-1937
Metabolic dysregulation reshapes the immune landscape: The gut microbiota-mTOR axis in respiratory viral infection immunity
- 24 December 2025
- Published by Elsevier in Molecular Therapy
- Vol. 34 (4) , 1921-1937
Open AccessMetabolic dysregulation reshapes the immune landscape: The gut microbiota-mTOR axis in respiratory viral infection immunity
- Open Access
- 27 August 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1655819
Personalized immunization to optimize vaccine immunogenicity: exploring the multidimensional effects of host intrinsic factors, external intervention strategies, and the external environment
Vaccines are a fundamental tool in the prevention and control of infectious diseases; however, significant individual variability in immunogenicity exists. This variability is not solely attributable to vaccine characteristics but is also influenced by a range of factors. This review systematically examines the key factors influencing vaccine immunogenicity, with particular emphasis on host-intrinsic factors (e.g., metabolic status, genetic background), personalized external interventions, such as optimized vaccine delivery techniques (e.g., aspiration-based skin delivery) and immunomodulatory adjuvant therapies (e.g., acupuncture, moxibustion, and near-infrared light therapy), as well as environmental exposures and immune memory. By examining the mechanisms and recent research advancements associated with these factors, this paper seeks to provide a foundation for the development of personalized vaccination strategies to address future public health challenges.
- 27 August 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1655819
Open AccessPersonalized immunization to optimize vaccine immunogenicity: exploring the multidimensional effects of host intrinsic factors, external intervention strategies, and the external environment
Vaccines are a fundamental tool in the prevention and control of infectious diseases; however, significant individual variability in immunogenicity exists. This variability is not solely attributable to vaccine characteristics but is also influenced by a range of factors. This review systematically examines the key factors influencing vaccine immunogenicity, with particular emphasis on host-intrinsic factors (e.g., metabolic status, genetic background), personalized external interventions, such as optimized vaccine delivery techniques (e.g., aspiration-based skin delivery) and immunomodulatory adjuvant therapies (e.g., acupuncture, moxibustion, and near-infrared light therapy), as well as environmental exposures and immune memory. By examining the mechanisms and recent research advancements associated with these factors, this paper seeks to provide a foundation for the development of personalized vaccination strategies to address future public health challenges.
- Open Access
- 14 August 2025
- Published by Elsevier in Molecular Therapy Nucleic Acids
- Vol. 36 (3) , 102687
The potential and challenges of circular RNA in the development of vaccines and drugs for emerging infectious diseases
- 14 August 2025
- Published by Elsevier in Molecular Therapy Nucleic Acids
- Vol. 36 (3) , 102687
Open AccessThe potential and challenges of circular RNA in the development of vaccines and drugs for emerging infectious diseases
- Open Access
- 13 August 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1618406
Harnessing cellular immunity for next-generation vaccines against respiratory viruses: mechanisms, platforms, and optimization strategies
Respiratory tract infections, such as influenza, respiratory syncytial virus (RSV) infection, and COVID-19, remain a persistent threat to global public health due to their high transmissibility and disease burden. Vaccination, as a key preventive strategy, not only reduces the risk of infection but also blocks transmission by activating adaptive immunity. While traditional vaccine evaluations have primarily focused on humoral immunity, growing evidence highlights the critical role of T lymphocyte-mediated cellular immunity in clearing virus-infected cells, establishing long-term immune memory, and responding to viral mutations. This review systematically summarizes the cellular immune responses induced by vaccines against respiratory tract infections and their correlation with protective efficacy. It also outlines evaluation methodologies such as flow cytometry, providing a theoretical foundation for optimizing vaccine design and assessment, and advancing the development of effective, broad-spectrum vaccines.
- 13 August 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1618406
Open AccessHarnessing cellular immunity for next-generation vaccines against respiratory viruses: mechanisms, platforms, and optimization strategies
Respiratory tract infections, such as influenza, respiratory syncytial virus (RSV) infection, and COVID-19, remain a persistent threat to global public health due to their high transmissibility and disease burden. Vaccination, as a key preventive strategy, not only reduces the risk of infection but also blocks transmission by activating adaptive immunity. While traditional vaccine evaluations have primarily focused on humoral immunity, growing evidence highlights the critical role of T lymphocyte-mediated cellular immunity in clearing virus-infected cells, establishing long-term immune memory, and responding to viral mutations. This review systematically summarizes the cellular immune responses induced by vaccines against respiratory tract infections and their correlation with protective efficacy. It also outlines evaluation methodologies such as flow cytometry, providing a theoretical foundation for optimizing vaccine design and assessment, and advancing the development of effective, broad-spectrum vaccines.